uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.
Regulation
